Why “reprogramming” is the buzziest approach to reversing aging right now

Life Biosciences dosed its first volunteer earlier this week with an experimental treatment designed to regenerate healthy nerves in the eye, aiming to reverse glaucoma. David Sinclair, chairman and cofounder of Life Biosciences, hopes this approach, which "reprograms" cells to a younger state, can be extended to reverse other age-related diseases and potentially aging itself. This "reprogramming" strategy is gaining significant traction among biotech companies exploring methods to slow and reverse the aging process. Aging is a complex phenomenon characterized by numerous biological changes, previously categorized by scientists into nine "hallmarks of aging" in a 2013 paper. While some targets, like telomere attrition, have seen fluctuating interest, the concept of cellular reprogramming is currently the most prominent strategy. Telomeres, protective DNA sequences at chromosome ends, shorten with cell division, eventually making DNA vulnerable. In 2015, Liz Parrish, CEO of BioViva, underwent an experimental gene therapy intended to lengthen her telomeres, reflecting earlier interest in this specific hallmark of aging. Despite continued research, telomere lengthening has not maintained the same level of public and scientific focus as cellular reprogramming currently does.